China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Leading Chinese drug maker Simcere Pharmaceutical Group, which develops innovative medicines, first-to-market generics and biosimilars, reported this week that its earnings for 2010 skyrocketed, despite its takeover of a vaccine producer that was slapped with substantial fines last year for turning out a "substandard rabies vaccine.
You may also be interested in...
China’ Simcere To Sell Its 35% Stake In Shanghai Celgen
China’sSimcere Pharmaceutical Group plans to sell its 35% stake in Shanghai Celgen Bio-Pharmaceutical Co. Ltd. for $48 million, exiting a deal signed in 2009.
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China